Overview
Lobbying Costs
100,000€ - 199,999€
Financial year: Jan 2022 - Dec 2022
Lobbyists (Full time equivalent)
0.5 Fte (1)
Lobbyists with EP accreditation
1
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Alexion Pharmaceuticals (Alexion)
EU Transparency Register
611074012464-89 First registered on 18 Dec 2013
Goals / Remit
Alexion Pharmaceuticals, Inc. now part of Astra Zeneca, is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope.
Main EU files targeted
Alexion monitors and follows policy of relevance for the biopharmaceutical sector. It interacts with the EU institutions and engages in issues relating to healthcare, pharmaceuticals, patient safety, research and innovation, competitiveness and internal market.
Address
Head Office
121 Seaport Boulevard
Boston MA 02210
UNITED STATESEU Office
Alexion Pharma GmbH Neuhofstrasse 34
Baar 6340
SWITZERLANDWebsite
-
People
Total lobbyists declared
1
Employment time Lobbyists 50% 1 Lobbyists (Full time equivalent)
0.5
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
1 accreditations were / are live (in bold) for the selected state of 20 Apr 2024
Name Start date End Date Matthias Heck 28 Jun 2023 27 Jun 2024 Mr Matthias HECK 28 Jun 2023 15 Apr 2024 Mr Matthias HECK 14 Feb 2020 01 Mar 2021 Mr Matthias HECK 02 Aug 2018 01 Sep 2019 Ms Claire Albano 17 Oct 2017 08 Jun 2018 Mr Thibault, Marie Bruno De Lary de Latour 17 Oct 2017 21 Sep 2018 Mr Matthias HECK 27 Jun 2017 21 Jun 2018 Ms Claire Albano 22 Oct 2016 17 Oct 2017 Mr Thibault, Marie Bruno De Lary de Latour 22 Oct 2016 17 Oct 2017 Mr Gregory KALBAUGH 30 Sep 2016 23 Sep 2017 Mr David Newman 22 Aug 2016 30 Jul 2017 Mr Matthias HECK 20 Feb 2016 19 Feb 2017 Ms Heidi Wagner 29 Oct 2015 23 Oct 2016 Ms Claire Albano 29 Oct 2015 22 Oct 2016 Mr Thibault, Marie Bruno De Lary de Latour 29 Oct 2015 22 Oct 2016 Ms Grainne Madeline Crowley 29 Oct 2015 23 Oct 2016 Mr Gregory KALBAUGH 04 Sep 2015 02 Sep 2016 Ms Grainne Madeline Crowley 20 Nov 2014 29 Oct 2015 Mr Thibault, Marie Bruno De Lary de Latour 20 Nov 2014 29 Oct 2015 Mrs Grainne Madeline Crowley 20 Nov 2014 27 Jan 2015 Ms Heidi Wagner 19 Nov 2014 29 Oct 2015 Mr André Zöller 19 Nov 2014 29 Jul 2015 Ms Claire Albano 19 Nov 2014 29 Oct 2015 Complementary Information
The Government Affairs team covers a broad range of activities that go beyond EU policies. This explains the percentage indicated for EU related activities.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Alexion is member of the following organisations in Brussels:
- EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
- EuropaBio
- EURORDIS Roundtable of Companies (ERTC) - European Organisation for Rare Diseases
- EFPIA (via Astra Zeneca)
- Friends of Europe
- Avicenna AllianceMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2022 - Dec 2022
Lobbying costs for closed financial year
100,000€ - 199,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount concilius 200,000€ - 299,999€ fipra 50,000€ - 99,999€ Intermediaries for current year
Name concilius Closed year Costs
100,000€ - 199,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
- Revision of EU Orphan Drug Legislation
- European Commission Pharmaceutical Strategy
- Potential amendments of Directive 2001/83 and Regulation 724/2006Other activities
Raise awareness in the field of severe and life-threatening rare and ultra-rare diseases for which few or no treatments exist, and which affect very small numbers of patients.
Alexion supports equal access to innovative and life-transforming therapies in the healthcare sector and actively engages in debates on issues relevant to the biopharmaceutical sector.
Meetings
Meetings
None declared